Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (December 2013)
26 slides from Harrow's investor presentation, Dec 16, 2013
Slide 1: Welcome
Welcome Imprimis Pharmaceuticals, Inc. Investor Update December 16, 2013
Slide 2: Robert J. Kammer
Robert J. Kammer Chairman, Imprimis Pharmaceuticals, Inc.
Slide 3: Mark L. Baum
Mark L. Baum CEO, Imprimis Pharmaceuticals, Inc.
Slide 4: Imprimis Accomplishments, Corporate Vision and 2014 Outlook
Imprimis Accomplishments Corporate Vision and 2014 Outlook
Slide 5: Imprimis Strategic Positioning
Imprimis Strategic Positioning NGEs Risk a Generics imprim! z < Reward >
Slide 6: 2013 Drivers of Healthcare
2013 Drivers of Healthcare pve ma », Ee i, Health Care Reform Drug Quality and Security Act (DQSA) New realities require a new way of thinki
Slide 7: The Compounding Pharmacy Model
The Compounding Pharmacy Model + Approx. 7,500 US compounding pharmacies governed by state pharmacy laws + Compounding pharmacists make patient-specific medications under physician's treatment directives + Repurpose the more than 7,800 FDA approved generic drugs to build new medicines
Slide 8: Bottom-Up Approach to Drug Development
Bottom-Up Approach to Drug Development R&D Clinical & Big Regulatory Pharma Sales & Marketing — Personalized Pharma
Slide 9: Personalized Medicine Today
Personalized Medicine 7oday The Prescriber-Pharmacist-Patient Triad Patient Pharmacis + Physicians and Pharmacists understand patient needs + Pharmacists customize medications for specific patient needs + The Triad can identify opportunities to help large numbers of patients
Slide 10: Key Accomplishments
Key Accomplishments Recapitalized the business Continued to develop innovative relationships with pharmacists and physicians Formalized our ARM process to evaluate innovation Acquired IP in four key therapeutic areas: Ophthalmology, Wound Management, Urology and Pain. Created Ophthalmology Division
Slide 11: Gary Seelhorst
Gary Seelhorst Vice President, Corporate Development Imprimis Pharmaceuticals, Inc.
Slide 12: Pipeline Assets and ARM Process
imprimis Pipeline Assets and ARM Process
Slide 13: How Our Business Works
How Our Business Works Eas “ Imprimis PHARMACEUTICALS
Slide 14: Patient-Focused Model
Patient-Focused Model FDA Commercialization Pathway {ot ate | 2) a | ‘Compounding Channels
Slide 15: Asset Review Methodology (ARM™)
Asset Review Methodology (ARM™)
Slide 16: John Saharek
John Saharek VP, Commercialization Ophthalmology Divisio Imprimis Pharmaceuticals, Inc.
Slide 17: "Go Dropless" Ophthalmic Division Overview
imprimis “Go Dropless” — Ophthalmic Division Overview
Slide 18: Ophthalmic Opportunity
Ophthalmic Opportunity > 3.5 Million cataract procedures annually ~ $1 Billion market for pre-op and post-op therapeutics > Drops make up a significant portion of this market Patient challenges with Drop Therapy > > Doctor challenges with Drop Therapy > > Compliance / A Cost - ‘0s: | > +> Staff Time
Slide 19: Creating a Market for TriMoxi
Creating a Market for TriMoxi Create ‘Awareness for TriMoxi Discourage Establish drop therapy “Establish dropsas the least preferred option Clearly define the downstream effects on clinic staff and patient ‘Raise awareness around compliance and cost issues pharmacologi ‘option for patients
Slide 20: Developing the Market
Developing the Market Build Imprimis ophthalmology commercial teangi i Identify and recruit Key Opinion Leaders (KOLs, Develop a pricing and access strategy Create clear concise messaging Implement a broad communication strategy > Ophthalmic Symposiums & Congresses > Podium Presentations » Trade Jou
Slide 21: 2014 Outlook
imprinis 2014 Outlook
Slide 22: 2014 Outlook
2014 Outlook * Compounding pharmacy facilities strategy ° Sell, make and distribute ophthalmology products * Launch business divisions in wound management, urology and pain * Begin scaling business to establish national footprint * Continue to hire key employees
Slide 23: Condensed Balance Sheet
Condensed Balance Sheet (Unaudited and Abbreviated) ASSETS September 20,2018 Current Assets Cash and short term investments $ 16,877,683 Other assets 525,609 TOTALASSETS $ 17,403,292 LIABILITIES AND STOCKHOLDERS' EQUITY —= = Accounts payable and other accruals $ 1,058,545 TOTAL LIABILITIES 1,058,545
Slide 24: Company Overview
Company Overview * Approx. $17M in cash as of September 30, 2013 ° Nominal debt; no preferred instruments ° Near, mid and long term catalysts * Strong key strategic / innovative relationships ° Experienced management team to execute
Slide 25: Questions?
impnimis Questions?
Slide 26: Thank You!
impnimis Thank You! Happy Holidays
Imprimis Pharmaceuticals — Investor Presentation (December 2013) on 6ix